Helping patients with difficult-to-treat cancers
Oncopeptides develops cancer therapies based on proprietary technology. We focus on diseases with significant unmet medical need, advancing science from discovery to commercialization.
WEBCAST
Invitation to presentation of the Q3 report 2026
Oncopeptides AB will publish the report for the third quarter 2026, at 08:00 CET November 5, 2026. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on November 5 at 09:00 CET.
Latest updates
For patients with few options, innovation offers hope
At Oncopeptides, we are dedicated to turning research into therapies that change lives. This is how we do it.
Our Science
We are innovative and curious, and committed to bringing innovation to patients with rare hematological diseases. We are passionate to make a difference for patients who have an urgent need for better treatment options.
Pepaxti
Melflufen is the first Peptide Drug Conjugate (PCD) with an alkylating payload. The drug utilizes peptidases and esterases that are overexpressed in multiple myeloma cells, to release a toxic payload inside cells, to damage DNA and kill cancer cells.
Pipeline
Through its two innovation platforms PDC and SPiKE, Oncopeptides aims to leverage its knowledge to develop new drugs addressing some of the most difficult-to-treat cancers.
A Journey of Innovation
Founded in 2000 by leading Swedish cancer researchers, Oncopeptides has spent over two decades advancing treatments for difficult-to-treat cancers.